115 related articles for article (PubMed ID: 32780524)
1. Cell death-inducing properties of selected dendrimers against different breast cancer and leukemia cell lines.
Baecker D; Kapp T; Schumacher P; Gust R; Kircher B
Arch Pharm (Weinheim); 2020 Nov; 353(11):e2000209. PubMed ID: 32780524
[TBL] [Abstract][Full Text] [Related]
2. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of Anticancer Action of Novel Imidazole Platinum(II) Complex Conjugated with G2 PAMAM-OH Dendrimer in Breast Cancer Cells.
Czarnomysy R; Muszyńska A; Rok J; Rzepka Z; Bielawski K
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070401
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and cytotoxic activity of G3 PAMAM-NH(2) dendrimer-modified digoxin and proscillaridin A conjugates in breast cancer cells.
Winnicka K; Bielawski K; Bielawska A
Pharmacol Rep; 2010; 62(2):414-23. PubMed ID: 20508299
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake of glucoheptoamidated poly(amidoamine) PAMAM G3 dendrimer with amide-conjugated biotin, a potential carrier of anticancer drugs.
Uram Ł; Szuster M; Filipowicz A; Zaręba M; Wałajtys-Rode E; Wołowiec S
Bioorg Med Chem; 2017 Jan; 25(2):706-713. PubMed ID: 27919613
[TBL] [Abstract][Full Text] [Related]
6. Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes.
Muñoz AM; Fragoso-Vázquez MJ; Martel BP; Chávez-Blanco A; Dueñas-González A; R García-Sánchez J; Bello M; Romero-Castro A; Correa-Basurto J
Anticancer Agents Med Chem; 2020; 20(15):1857-1872. PubMed ID: 32324521
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium dendrimers against acute promyelocytic leukemia:
Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Abashkin V; Dzmitruk V; Rogalska A; Denel M; Gapinska M; Shcharbin D; Gomez Ramirez R; de la Mata FJ; Bryszewska M
Future Med Chem; 2019 Jul; 11(14):1741-1756. PubMed ID: 31287722
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium Dendrimers against Human Lymphoblastic Leukemia 1301 Cells.
Michlewska S; Ionov M; Szwed A; Rogalska A; Sanz Del Olmo N; Ortega P; Denel M; Jacenik D; Shcharbin D; de la Mata FJ; Bryszewska M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526993
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic activity of G3 PAMAM-NH₂ dendrimer-chlorambucil conjugate in human breast cancer cells.
Bielawski K; Bielawska A; Muszyńska A; Popławska B; Czarnomysy R
Environ Toxicol Pharmacol; 2011 Nov; 32(3):364-72. PubMed ID: 22004955
[TBL] [Abstract][Full Text] [Related]
10. Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines.
Haririan I; Alavidjeh MS; Khorramizadeh MR; Ardestani MS; Ghane ZZ; Namazi H
Int J Nanomedicine; 2010 Feb; 5():63-75. PubMed ID: 20161988
[TBL] [Abstract][Full Text] [Related]
11. para-Sulfonatocalix[4]arene and polyamidoamine dendrimer nanocomplexes as delivery vehicles for a novel platinum anticancer agent.
Pang CT; Ammit AJ; Ong YQE; Wheate NJ
J Inorg Biochem; 2017 Nov; 176():1-7. PubMed ID: 28810174
[TBL] [Abstract][Full Text] [Related]
12. Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation.
Wang F; Cai X; Su Y; Hu J; Wu Q; Zhang H; Xiao J; Cheng Y
Acta Biomater; 2012 Dec; 8(12):4304-13. PubMed ID: 22842039
[TBL] [Abstract][Full Text] [Related]
13. Structural dependence of in vitro cytotoxicity, oxidative stress and uptake mechanisms of poly(propylene imine) dendritic nanoparticles.
Khalid H; Mukherjee SP; O'Neill L; Byrne HJ
J Appl Toxicol; 2016 Mar; 36(3):464-73. PubMed ID: 26671548
[TBL] [Abstract][Full Text] [Related]
14. Design considerations for PAMAM dendrimer therapeutics.
Goonewardena SN; Kratz JD; Zong H; Desai AM; Tang S; Emery S; Baker JR; Huang B
Bioorg Med Chem Lett; 2013 May; 23(10):2872-5. PubMed ID: 23583511
[TBL] [Abstract][Full Text] [Related]
15. Thermoresponsive dendrimers based on oligoethylene glycols: design, synthesis and cytotoxic activity against MCF-7 breast cancer cells.
Abdel-Rahman MA; Al-Abd AM
Eur J Med Chem; 2013 Nov; 69():848-54. PubMed ID: 24121308
[TBL] [Abstract][Full Text] [Related]
16. Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines.
Uram Ł; Filipowicz A; Misiorek M; Pieńkowska N; Markowicz J; Wałajtys-Rode E; Wołowiec S
Eur J Pharm Sci; 2018 Nov; 124():1-9. PubMed ID: 30118847
[TBL] [Abstract][Full Text] [Related]
17. G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity.
Goldberg DS; Vijayalakshmi N; Swaan PW; Ghandehari H
J Control Release; 2011 Mar; 150(3):318-25. PubMed ID: 21115079
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antiproliferative activity of novel steroidal dendrimer conjugates.
Magaña-Vergara NE; Rárová L; Soto-Castro D; Farfán N; Strnad M; Santillan R
Steroids; 2013 Dec; 78(12-13):1254-62. PubMed ID: 24060952
[TBL] [Abstract][Full Text] [Related]
19. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
Marcinkowska M; Stanczyk M; Janaszewska A; Sobierajska E; Chworos A; Klajnert-Maculewicz B
Pharm Res; 2019 Sep; 36(11):154. PubMed ID: 31482205
[TBL] [Abstract][Full Text] [Related]
20. Flavokawain derivative FLS induced G2/M arrest and apoptosis on breast cancer MCF-7 cell line.
Ali NM; Akhtar MN; Ky H; Lim KL; Abu N; Zareen S; Ho WY; Alan-Ong HK; Tan SW; Alitheen NB; Ismail JB; Yeap SK; Kamarul T
Drug Des Devel Ther; 2016; 10():1897-907. PubMed ID: 27358555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
